While receiving a metastatic cancer diagnosis can be overwhelming, it is important to keep in mind that not all cancers are ...
Boston Cell Standards, Inc. (BCS), a private company bringing modern Quality tools and practices to Clinical ...
Caris Life Sciences aims to standardize MET immunohistochemistry testing for non-squamous non-small cell lung cancer to enhance molecular insights and treatment personalization. MET protein expression ...
The FDA granted tumor-agnostic accelerated approval to trastuzumab deruxtecan (Enhertu) for previously treated unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid cancers.
Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease Codes in Patient Records Table 1.
Researchers from Lund University (Sweden) have investigated the tumor immune microenvironment of primary triple-negative breast cancer using digital image analysis of IHC-stained immune cells. To do ...
Impact of Bone Metastasis in Stage IV Non–Small Cell Lung Cancer Treated With Durvalumab and Tremelimumab With or Without Chemotherapy: A Retrospective Analysis of the CCTG BR.34 Trial Human epidermal ...
Continued approval of this tumor agnostic indication is contingent upon verification of clinical benefit in a confirmatory trial. The Food and Drug Administration (FDA) has granted accelerated ...
The highest rates of HER2 positivity were observed in bladder cancer, uterine serous carcinoma, and esophagogastric junction cancer. New research suggests the incidence of HER2 positivity is low ...
BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results